Premium
High‐dose chemotherapy with autologous stem cell transplantation spares re‐irradiation for recurrent intracranial germinoma
Author(s) -
Kubota Hirohito,
Umeda Katsutsugu,
Kagehiro Kouzuki,
Tanaka Kuniaki,
Daifu Tomoo,
Hamabata Takayuki,
Nodomi Seishiro,
Kato Itaru,
Hiramatsu Hidefumi,
Arakawa Yoshiki,
Mizowaki Takashi,
Adachi Souichi
Publication year - 2018
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27104
Subject(s) - medicine , melphalan , germinoma , chemotherapy , ifosfamide , total body irradiation , autologous stem cell transplantation , transplantation , surgery , salvage therapy , oncology , cyclophosphamide , etoposide
The clinical outcome of high‐dose chemotherapy (HDC) with autologous stem cell transplantation was retrospectively analyzed in six patients with recurrent intracranial germinoma. Prior to HDC, all patients achieved complete remission after platinum and ifosfamide‐based chemotherapy. A melphalan‐based conditioning regimen was administered in either a single cycle or multiple sequential cycles. Five of the six patients are alive and free from disease, with a median survival of 65 months, among which four patients avoided re‐irradiation. In a significant proportion of patients, recurrent intracranial germinoma is curable by HDC without re‐irradiation, provided that the disease remains sensitive to salvage chemotherapy.